June 16th 2025, 7:00pm
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.
June 16th 2025, 4:11pm
The 2025 ASCO Annual Meeting highlighted key advances in brain cancer and brain metastases for patients affected by the disease.
June 16th 2025, 1:00pm
The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs. Joshua K. Sabari and Manmeet Singh Ahluwalia.
June 13th 2025, 8:00pm
Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.
June 13th 2025, 4:00pm
Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert oncologists.
June 13th 2025, 1:16pm
Dr. Joshua K. Sabari and Dr. Prantesh Jain delve into key lung cancer outcomes from the 2025 ASCO Meeting that patients should be aware of.
June 12th 2025, 8:00pm
Expert oncologists Dr. Joshua K. Sabari and Dr. Eric K. Singhi break down key updates and takeaways in lung cancer treatment following ASCO 2025.
June 12th 2025, 4:00pm
Dr. Joshua K. Sabari and Dr. Daniel V. Araujo provide expert insights into genitourinary cancer updates from ASCO 2025.
June 11th 2025, 8:00pm
Dr. Joshua K. Sabari sat down with Dr. Daniel V. Araujo to discuss topline takeaways from the 2025 ASCO Meeting across the realm of genitourinary oncology
June 11th 2025, 4:30pm
Treatment with the investigational therapeutic rusfertide has proven to be a potential treatment option for patients with polycythemia vera.
Top Genitourinary Cancer Stories From September to Know
Understanding Stage 2 Kidney Cancer (Renal Cell Carcinoma)
Why Is Patient Advocacy Important During Breast Cancer Awareness Month?
Reclaiming Intimacy for Women After Cancer